---
title: "EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/273226026.md"
datetime: "2026-01-21T12:00:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/273226026.md)
  - [en](https://longbridge.com/en/news/273226026.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/273226026.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/273226026.md) | [繁體中文](https://longbridge.com/zh-HK/news/273226026.md)


# EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention

Ionis Pharmaceuticals Inc. and Otsuka Pharmaceutical Co., Ltd. announced that the European Commission has approved DAWNZERA™ (donidalorsen) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older in the European Union. The approval is based on positive results from the Phase 3 OASIS-HAE and OASISplus studies, where DAWNZERA demonstrated a significant reduction in HAE attack rates. Otsuka holds exclusive rights to commercialize DAWNZERA in Europe and Asia Pacific. With this approval, Ionis is eligible for a milestone payment of $15 million and tiered royalties up to 30% on net product sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260119050072) on January 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相关股票

- [Otsuka Pharmaceutical (OTSKY.US)](https://longbridge.com/zh-CN/quote/OTSKY.US.md)
- [Ionis Pharma (IONS.US)](https://longbridge.com/zh-CN/quote/IONS.US.md)
- [Otsuka Holdings Co., Ltd. (4578.JP)](https://longbridge.com/zh-CN/quote/4578.JP.md)

## 相关资讯与研究

- [Otsuka Holdings Grants Restricted Stock to Directors Tied to Medium-Term Performance Targets](https://longbridge.com/zh-CN/news/280743257.md)
- [Ionis Pharmaceuticals Repriced Drug Ahead Of Key FDA Decision Signals Push Into Larger Market](https://longbridge.com/zh-CN/news/280675376.md)
- [KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From EKTERLY Study](https://longbridge.com/zh-CN/news/281025028.md)
- [NHS clears Wegovy to reduce risk of heart attack and stroke](https://longbridge.com/zh-CN/news/281323250.md)
- [UK Regulator Recommends Novo Nordisk's Wegovy for People at Risk of Heart Attacks, Strokes](https://longbridge.com/zh-CN/news/281294814.md)